Andy Feinstein

Andy Feinstein has a diverse work experience spanning over several years. Andy most recently worked at Karuna Therapeutics as a Senior Director of Insights and Analytics starting in December 2022. Prior to that, they held the position of Director Commercial Analytics Business Partner at Sunovion Pharmaceuticals from May 2021 to December 2022. Before that, they served as a Principal at ASA Insights LLC from February to May 2021.

In 2020, Andy joined BioXcel Therapeutics Inc. as an Executive Director from July 2020 to January 2021. Andy also worked at Allergan, where they held the roles of Executive Director of Business Insights & Analytics from March 2019 to July 2020 and Director of Business Insights & Analytics from November 2016 to March 2019.

From 2011 to 2016, Andy worked at Novo Nordisk A/S as an Associate Director. In this role, they held responsibilities related to analytics and insights. Before that, they gained valuable experience as a Product Manager - Daxas at Forest Laboratories from November 2007 to February 2011.

Andy began their career in 1997 at JPMorgan, where they worked in investment banking until 2001. In 2005, they joined Novo Nordisk A/S as a Management Associate.

Overall, Andy Feinstein has built a successful career in analytics and insights within the pharmaceutical and finance industries, holding various managerial and leadership roles throughout their career.

Andy Feinstein completed an Online Certificate in Business Analytics: From Data to Insights at The Wharton School in 2020. Prior to that, they pursued an MBA in Finance at Fordham University School of Law from 2002 to 2004. In 2004 and 2005, Andy attended the Fordham Gabelli School of Business, although the degree and field of study for that period were not specified.